07:08 AM EDT, 07/24/2024 (MT Newswires) -- Boston Scientific ( BSX ) reported Q2 adjusted earnings Wednesday of $0.62 per diluted share, up from $0.53 a year earlier.

Analysts polled by Capital IQ expected $0.58.

Net sales for the quarter ended June 30 were $4.12 billion, up from $3.6 billion a year earlier.

Analysts polled by Capital IQ expected $4.02 billion.

The company raised its 2024 outlook for adjusted EPS to between $2.38 and $2.42 on net sales growth of 13.5% to 14.5%. The company previously guided $2.29 to $2.34 per share on a revenue increase of 11% to 13%.

Analysts surveyed by Capital IQ expect an adjusted EPS of $2.33 and a revenue of $16 billion.

For Q3, adjusted EPS is anticipated to be from $0.57 to $0.59 on net sales growth of 13% to 15%. Analysts surveyed by Capital IQ expect an adjusted EPS of $0.57 on revenue of $3.95 billion.

Shares of the company were up 1% in recent Wednesday premarket activity.

Price: 79.35, Change: +0.76, Percent Change: +0.97